P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB

Ngā tūemi rite

• P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
  mā: Mazyar Shadman, me ētahi atu.
  I whakaputaina: (2023-08-01)
• Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
  mā: Linlin Xu, me ētahi atu.
  I whakaputaina: (2024-01-01)
• PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
  mā: M. Shadman, me ētahi atu.
  I whakaputaina: (2022-06-01)
• Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
  mā: Constantine S. Tam, me ētahi atu.
  I whakaputaina: (2026-02-01)
• Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China
  mā: Ying Liu, me ētahi atu.
  I whakaputaina: (2026-03-01)